SCHEMBL3683175

SCHEMBL3683175

O=C(N1CCCC(c2ccccc2)C1)C1(Sc2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.59
ALDH1A1 P00352 5/20 0.50
LMNA P02545 2/20 0.48
HPGD P15428 2/20 0.48
HIF1A Q16665 1/20 0.48
NR1H2 P55055 1/20 0.47
NR1H3 Q13133 1/20 0.47
POLB P06746 2/20 0.46
MAPT P10636 2/20 0.46
TSHR P16473 1/20 0.46
RECQL P46063 1/20 0.46
RAB9A P51151 4/20 0.45
NPC1 O15118 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 1/20 0.45
PROKR1 Q8TCW9 1/20 0.44
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3684855 0.82 SCD5 (0.53) HSD11B1ALDH1A1MAPTRAB9ANPC1
SCHEMBL3680440 0.78 HSD11B1 (0.59) HSD11B1LMNAMAPTRAB9ANPC1
SCHEMBL27878990 0.77 ALDH1A1 (0.62) HSD11B1ALDH1A1LMNAHPGDHIF1A
SCHEMBL3312540 0.77 ALDH1A1 (0.62) HSD11B1ALDH1A1LMNAHPGDHIF1A
SCHEMBL349904 0.74 HSD11B1 (1.00) HSD11B1
SCHEMBL23009741 0.74 ALDH1A1 (0.59) HSD11B1ALDH1A1LMNAHPGDHIF1A
SCHEMBL20738480 0.74 ALDH1A1 (0.60) HSD11B1ALDH1A1LMNAHPGDHIF1A
SCHEMBL21424973 0.74 ALDH1A1 (0.59) HSD11B1ALDH1A1LMNAHPGDHIF1A
SCHEMBL21425067 0.74 ALDH1A1 (0.59) HSD11B1ALDH1A1LMNAHPGDHIF1A
SCHEMBL20738614 0.74 ALDH1A1 (0.60) HSD11B1ALDH1A1LMNAHPGDHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2243494-A1 Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. OntoChem GmbH (DE) 2010-10-27 EP claimed
US-20060009491-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-01-12 US claimed
EP-2243494-A1 Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. OntoChem GmbH (DE) 2010-10-27 EP disclosed
EP-1773773-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-07-29 EP disclosed
EP-1773773-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP disclosed
US-20060009491-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-01-12 US disclosed
WO-2006002350-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009491-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885ALDH1A1 311/4885LMNA 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.